Ziopharm Oncology (ZIOP) Misses Q1 EPS by 1c

Ziopharm Oncology (NASDAQ: ZIOP) reported Q1 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08).

“We anticipate reporting milestones across all of our programs this year, even when factoring in the effects of the pandemic on our global community, and we are working to minimize the uncertainty around some of our timelines,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer. “We continue to make progress toward initiating our TCR-T clinical trial at MD Anderson Cancer Center based on the Sleeping Beauty platform and look forward to providing an update on the status of this trial later this year. In our Controlled IL-12 platform for recurrent glioblastoma (rGBM), clinicians and healthcare workers continue to treat patients and facilitate patient enrollment and our anticipated milestones in this program are on track. The National Cancer Institute (NCI) and MD Anderson have limited nonclinical and clinical research in response to COVID-19 which impacts their partners, and which will temporarily delay the initiation of our clinical trials with each institution. We are working closely with them to undertake our trials once the restrictions ease; however, the timing is not under our control.”

“The Company is in a strong financial position, having completed a financing during the first quarter prior to the impact of the pandemic in the United States,” added Sath Shukla, Chief Financial Officer. “With over $170 million in cash and investments available to support our programs, we are well positioned to weather this storm and continue executing on our strategic objectives.”

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c